Ophthalmology News

Ophthalmology News

Featured Ophthalmology Job

Missouri Ophthalmologist LL3200 - northeast - $ 197 K (per year) + Leadership Role + Leadership Role

Thu, 13 Nov 2008 13:45:00 GMT

BE/BC Ophthalmologist needed in northeastern Missouri to join a multispecialty group. Experienced candidate desired who will transition into a leadership role. Hospital has just invested a million dol...

Delcath Systems Granted Orphan-Drug Designations For Cutaneous And Ocular Melanoma

Wed, 19 Nov 2008 00:00:00 PST

Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced that the United States Food and Drug Administration ("FDA") granted to Delcath two orphan-drug applications for the drug melphalan. Delcath was granted designations of the drug melphalan for the treatment of patients with cutaneous as well as ocular melanoma.

Experimental Drug RGN-259 Promotes Healing In Patients With Non-Healing Corneal Ulcers - Four Patients Treated Under "Compassionate Use" IND

Tue, 18 Nov 2008 10:00:00 PST

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that its ophthalmic drug candidate, RGN-259, was used to treat four neurotrophic keratitis patients with non-healing eye ulcers caused primarily by the herpes zoster virus under a "Compassionate Use" IND (Investigational New Drug application). RGN-259 is a sterile eye drop formulation of Tβ4 being developed by RegeneRx for use in treating ophthalmic wounds and related disorders. Dr.

Novagali Pharma S.A. Withdraws Its Marketing Authorisation Applicationfor Vekacia (ciclosporin)

Tue, 18 Nov 2008 08:00:00 PST

The European Medicines Agency (EMEA) has been formally notified by Novagali Pharma S.A. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vekacia (ciclosporin) 0.05% eye drops. Vekacia was expected to be used for the treatment of vernal keratoconjunctivitis. Vekacia was designated as an orphan medicine on 6 April 2006.

New Research Into Drug Delivery To Treat Eye Disease Highlighted By Conference Report

Tue, 18 Nov 2008 08:00:00 PST

Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. The report (http://www.iovs.

Promising Proof-of-Concept Data For Lpath's Ocular Drug Candidate ISONEP(TM) Published

Mon, 17 Nov 2008 04:00:00 PST

Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP(TM), Lpath's Phase 1 anti-S1P antibody, demonstrating promising results in various animal models of ocular disorders. The findings of the study appeared online ahead of print in the

Patents Issued For Inotek Pharmaceuticals' Lead Clinical Compounds In Glaucoma And Contrast-Induced Nephropathy

Sun, 16 Nov 2008 00:00:00 PST

Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company's two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Patent number 7,432,369 relates to INO-4885, in clinical development for the prevention of contrast-induced nephropathy.